

Hyperhidrosis (excess sweating) treatment of Palms or Axillae Policy



Quality & Equality First

VERSION CONTROL

Version:	3.0
Ratified by:	NHS Warwickshire North Governing Body
Date ratified:	1 September 2016
Name of originator/author:	Joint CCG Clinical Commissioning Policy Development Group
Name of responsible committee:	Commissioning, Finance and Performance Committee
Date issued:	1 September 2016
Review date:	1 September 2019

VERSION HISTORY

Date	Version	Comment / Update
April 2009	1.0	Previous PCT policy
June 2013	2.0	Version to Governing Body – approved on 12 June 2013
	3.0	

Treatment	Hyperhidrosis (excess sweating) treatment of Palms or Axillae
Indication	Hyperhidrosis (excess sweating) of the palms or axillae
Funding Status	Not routinely funded

OPCS	
Treatment:	Botulinum Toxin Therapy, Iontophoresis and surgical interventions for the treatment of Hyperhidrosis are not funded on the grounds of insufficient evidence of cost-effectiveness for them to be provided routinely to all patients
Equality Impact	See EIA attached

Equality Impact Assessment

Policy	Hyperhidrosis	Person completing EIA	Clive Campton, Individual Funding Request (IFR) Team Lead & Public Health
Date of EIA	December 2015	Accountable CCG Lead	Jenni Northcote, Director of Partnerships and Engagement

Aim of Work	To assess the impact of the policy on all of the protected groups.
Who Affected	Warwickshire North registered patients

Single Equality Scheme Strand	Likely to be a differential impact?	Single Equality Scheme Strand	Likely to be a differential impact?
Gender	No	Age	No
Race	No	Social deprivation	No
Disability	No	Carers	No
Religion / belief	No	Human rights	No
Sexual orientation	No	Other	No

Describe any potential or known adverse impacts or barriers for protected/vulnerable groups and what actions will be taken (if any) to mitigate. If there are no known adverse impacts, please explain.

The impact of this policy has been considered against all protected characteristics and Human Rights values.

No potential or known adverse impacts or barriers for protected and/or vulnerable groups were identified.

Clinical Members of the Arden Policy Development Group which oversaw policy revision:

Sue Turner Dr Chris Pycock Yadav Deepika Dr Steve Allen Dr Adrian Parsons Kathryn Millard	WNCCG Governing Body Member (Practice Network Clinical Lead) WNCCG Secondary Care Liaison CRCCG Member of CCG Executive Team, GP CRCCG Governing Body Member (Chief Clinical Officer), GP SWCCG Governing Body Member, GP WCC Public Health Consultant
--	---

Quality Impact Assessment

QIA Completed By: Sue Turner, WNC CG Practice Network Clinical Lead				Date Completed: 04 July 2016					
HYPERHIDROSIS AREA OF ASSESSMENT		OUTCOME ASSESSMENT			Evidence/Comments for answers	Risk rating (For negative outcomes)			Mitigating actions
		Positive	Negative	Neutral		Risk impact (I)	Risk likelihood (L)	Risk Score (IxL)	
Duty of Quality Could the scheme impact positively or negatively on any of the following	Effectiveness – clinical outcome			X	No change to policy.				
	Patient experience			X					
	Patient safety			X					
	Parity of esteem			X					
	Safeguarding children or adults			X					
NHS Outcomes Framework Could the scheme impact positively or negatively on the delivery of the five domains:	Enhancing quality of life			X					
	Ensuring people have a positive experience of care			X					
	Preventing people from dying prematurely			X					
	Helping people recover from episodes of ill health or following injury			X					
	Treating and caring for people in a safe environment and protecting them from avoidable harm			X					
Patient services Could the proposal impact positively or negatively on any of the following:	A modern model of integrated care, with key focus on multiple long-term conditions and clinical risk factors			X					
	Access to the highest quality urgent and emergency care			X					
	Convenient access for everyone			X					
	Ensuring that citizens are fully included in all aspects of service design and change			X					
	Patient Choice			X					
	Patients are empowered in their own care			X					
	Wider primary care, provided at scale			X					